CXCR5 antagonists and methods of treating diseases or disorders using same
US12414927B2 · kind B2 · utility
0Cited by
0References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 30, 2021 |
| Grant date | Sep 16, 2025 |
| Priority date | — |
| Expiry date | Sep 20, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides compounds, and compositions comprising such compounds, that can be used to treat CXCR5-expressing cancers, especially angioimmunoblastic T cell lymphoma (AICL) and/or cutaneous T cell lymphoma (CTCL).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.